Compare ASAN & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASAN | TNDM |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2020 | 2013 |
| Metric | ASAN | TNDM |
|---|---|---|
| Price | $5.86 | $14.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 19 |
| Target Price | $12.46 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 6.8M | 2.0M |
| Earning Date | 06-02-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $790,806,000.00 | ★ $1,014,736,000.00 |
| Revenue This Year | $10.19 | $8.11 |
| Revenue Next Year | $7.91 | $11.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 9.25 | 7.93 |
| 52 Week Low | $5.38 | $10.00 |
| 52 Week High | $19.00 | $29.65 |
| Indicator | ASAN | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 41.62 | 30.44 |
| Support Level | $5.87 | $13.24 |
| Resistance Level | $6.78 | $15.75 |
| Average True Range (ATR) | 0.40 | 1.33 |
| MACD | -0.08 | -0.50 |
| Stochastic Oscillator | 13.17 | 9.09 |
Asana Inc is the system of action for work, built for the Agentic Enterprise. It provides a comprehensive solution where humans and AI agents can collaborate effectively so that individuals work smarter, teams move faster, and organizations deliver results. Companies use Asana to connect their work to company goals and orchestrate mission-critical workflows like product launches, employee onboarding, resource planning, tracking company-wide strategic initiatives and more. It manages its operations and allocates resources as a single operating and reportable segment. The company generates revenues from subscriptions from paying customers accessing its cloud-based platform.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.